DEA Rescheduling May Leave Hemp-Derived THCA Fully Legal

Schedule III Placement Preserves Hemp Exemption

Moving marijuana to Schedule III doesn't amend the 2018 Farm Bill's definition of hemp, which hinges solely on delta-9 THC concentration. The Farm Bill carved hemp out of the Controlled Substances Act entirely. Any cannabis plant with ≤0.3% delta-9 THC is a legal agricultural commodity. Schedule III applies only to marijuana—cannabis exceeding that threshold.

THCA, the non-psychoactive acid precursor to delta-9 THC, isn't measured in the Farm Bill's 0.3% limit. Hemp flower can contain 15-20% THCA by dry weight and still qualify as legal hemp if its delta-9 THC stays below 0.3%. Heat converts THCA into delta-9 THC through decarboxylation at roughly 87% efficiency.

Conversion Chemistry Unchanged by Rescheduling

Rescheduling marijuana doesn't regulate chemical processes applied to legal hemp. Isomerization—the chemical conversion of CBD or other cannabinoids into delta-8 THC, delta-10 THC, or THC-O—remains technically legal if the starting material is Farm Bill–compliant hemp. The DEA has issued interim final rules asserting that synthetically derived cannabinoids fall under Schedule I, but those rules face legal challenges and haven't been uniformly enforced.

If marijuana moves to Schedule III, state-licensed cannabis programs would operate under stricter federal oversight while hemp-derived products continue flowing through unregulated channels. The regulatory gap widens rather than closes.

State Enforcement Diverges on Hemp-Derived THC

At least 19 states have moved to restrict or ban hemp-derived intoxicating cannabinoids since 2022, but enforcement remains inconsistent. Minnesota, Oregon, and California have imposed testing requirements or age restrictions on hemp-derived delta-9 products. Texas and Florida have issued cease-and-desist letters to retailers selling THCA flower. Prosecutions are rare. In states without explicit hemp-THC bans, products labeled as hemp-derived continue to sell in gas stations, smoke shops, and online.

Schedule III placement doesn't grant the DEA or FDA new authority over hemp. The USDA retains primary regulatory jurisdiction under the Farm Bill, and USDA hasn't proposed amending the delta-9 measurement standard.

Industry Arbitrage Expands Under Split Regime

MSOs operating under state cannabis licenses face 280E tax burdens and state excise rates averaging 20-37%, while hemp-derived competitors pay standard corporate tax rates and no cannabis excise. A Schedule III marijuana industry would gain some tax relief through 280E repeal, but state taxes and seed-to-sale tracking costs remain. Hemp-derived products bypass both.

The price gap is stark. THCA flower retails for $80-$120 per ounce in hemp shops, compared to $200-$350 per ounce in state-licensed dispensaries. Consumers in non-legal states increasingly turn to hemp-derived products that ship via USPS.

Congressional Fix Unlikely Before 2027

The 2023 Farm Bill reauthorization stalled without amending hemp's THC definition, and no standalone bill has advanced to address conversion loopholes. Senate Majority Leader Chuck Schumer has prioritized comprehensive cannabis reform over incremental hemp fixes, but the SAFER Banking Act remains stalled in the House. Representative Mary Miller introduced HR 4223 in June 2025 to close the THCA loophole by measuring total THC. The bill died in committee.

The next Farm Bill cycle opens in late 2027. Until then, the 0.3% delta-9 standard stands.

DEA's Rescheduling Timeline and Legal Challenges

The DEA's Notice of Proposed Rulemaking on Schedule III placement entered public comment on May 21, 2024, with a comment period that closed August 22, 2024. The agency hasn't published a final rule. Administrative law experts estimate final rulemaking by Q4 2026 at the earliest, assuming no legal challenges. Multiple industry groups have filed comments opposing Schedule III as either too restrictive or insufficiently protective of state programs.

If rescheduling proceeds, implementation would require coordination with the FDA on research protocols, prescribing guidelines, and interstate commerce rules. That process typically takes 12-18 months after a final rule is published.

What Operators and Regulators Should Watch

The hemp-marijuana regulatory split isn't a drafting error—it's a structural feature of overlapping statutes that rescheduling doesn't resolve. State regulators in legal markets are already lobbying for federal preemption of hemp-derived intoxicants, but the legal path is unclear. The FDA could assert jurisdiction under the Food, Drug, and Cosmetic Act, but the agency hasn't prioritized hemp enforcement.

For background on the DEA's rescheduling process and timeline, see the CannIntel topic hub on DEA rescheduling. Operators should monitor state-level hemp bills in the 2027 legislative session and plan for divergent compliance regimes across state lines. This remains legally unsettled territory, and enforcement will vary sharply by jurisdiction.